The Korean Derma Cosmetics Trend: A Founder's Guide to the Segment

Walk into an Olive Young in Seoul and one shelf looks like a pharmacy counter: short ingredient lists, clinical white packaging, a drug maker's name on the box. That shelf is now landing in US retail. Dongkook Pharmaceutical put its Centellian24 line into 1,400 Ulta Beauty stores in May 2026 (The Guru).

This guide covers what "derma" means and who built the segment in Korea. It also covers why some drug companies failed at it, and how to brief a Korean ODM without drifting into drug claims.

What Are Derma Cosmetics, Exactly?

Derma cosmetics are skincare products positioned on dermatology science, usually through a pharmaceutical or clinic origin, a well-studied soothing or repair ingredient, and human test data. The name comes from dermatology. Neither Korea nor the US defines it in law.

Business Watch describes the label as a signal that a product was developed with hospitals or drug companies. These brands sell with numbers and clinical data rather than mood words (Business Watch). The US view lines up. The FDA says the industry term "cosmeceutical" has no meaning under the law. A product that claims to treat or prevent disease, or to change how the body works, is a drug (FDA).

So the product is still a cosmetic. It earns its credibility through the ingredient, the test file and restraint on the label.

The Numbers Behind Korea's Derma Boom

Korea's derma cosmetics segment is estimated at about 5.5 trillion won by the Korea Corporate Reputation Research Institute. That is close to ten times its size five years ago (The Guru). Over the same stretch, the traditional cosmetics market stalled.

The global trend points the same way. Citing Euromonitor and Fortune Business Insights, Business Watch puts the global category at about 71 trillion won in 2025, up 45% from 2022. It grew 13% a year from 2020 to 2024, against 1.7% for skincare overall (Business Watch).

L'Oréal, the category's biggest player, reported that its Dermatological Beauty division grew 5.5% in 2025 and outpaced the global dermo-cosmetics market (CosmeticsDesign Europe). Korea's own base keeps expanding as well: MFDS data put 2025 cosmetics exports at $11.4 billion, a record (Cosinkorea).

Who Builds Korean Derma Brands?

Three kinds of companies built the segment: drug makers that turned a pharmacy ingredient into skincare, dermatology clinics that became brands, and cosmetics groups that grew clinical lines out of their own drug affiliates. Each started with a proof asset shoppers already trusted.

The deal record tells the same story. LG H&H bought CNP in 2014, Domina cream maker Taeguk Pharm in 2017 and Physiogel's Asia and North America rights in 2020 (Business Watch). If you are building toward an exit, the buyer side of this trend is covered in our guide to who buys K-beauty brands.

Pharma Money Alone Did Not Win

A drug company name is not a strategy. An October 2026 Cosinkorea review found that drug makers who bought cosmetics companies struggled, while those that moved a proven drug-side ingredient into an everyday product grew (Cosinkorea).

The misses are specific. KOSDAQ approved the delisting of SD Biotechnologies, the mask-pack maker controlled by Daewon Pharmaceutical, on October 6, 2026. Yuhan's cosmetics affiliate, now Yuhan Cosmetic, saw sales fall more than 98% between 2019 and 2025 (same review). Celltrion Skincure posted operating losses in most years since 2017. Dongwha's Hwalmyung skincare struggled to turn its digestive-tonic heritage into lasting demand.

The winners share one move. Dongkook carried its centella know-how from a wound ointment into Madeca Cream, and Daewoong built Easydew around its own EGF. Dongkook then bought an ODM, Rebom Cosmetics, in 2024 to bring production in-house. For an indie brand the parallel is one defensible proof asset: an ingredient with published data, a supplier story you can document, or test results you can show a buyer.

What Goes Into a Derma Brief for a Korean ODM?

A good brief starts from the proof asset and works outward: one hero ingredient with published data, a short base without added fragrance, a test plan matched to each claim, and protective packaging. Korean ODMs can deliver all four, but only when the brief asks for them.

1. Name the proof asset. Pick one hero with a record you can cite, such as centella and madecassoside, panthenol, ceramides or EGF. Our centella and madecassoside guide and EGF sourcing guide cover grades and rules; soothing botanicals such as heartleaf work as supporting actives.
2. Keep the base short. Hwahae's 2026 trend report named high-function minimalism and safe soothing as the year's key words (Business Watch). Ask for a version without added fragrance and an INCI list that states the job of each ingredient.
3. Match each test to a claim. A patch test supports a mildness statement; a human application test supports an efficacy number. Our HRIPT vs clinical vs consumer testing guide maps which test backs which claim.
4. Protect the formula. Airless pumps and tubes limit contamination for lighter preservative systems. Compare formats in our packaging guide.
5. Write the spec for barrier work. If the hero is barrier repair, our barrier repair formula spec lists the ceramide, polyglutamic acid and panthenol choices to put in the brief.

Ask for both markets' paperwork at once: any MFDS functional cosmetic status, plus the safety and stability files a US responsible person needs under MoCRA. The FDA requirements guide for Korean skincare imports lists the US side.

Where Derma Claims Cross the Line in Korea and the US

Both countries regulate the claim, not the word "derma." In Korea, a cosmetic ad cannot read like a drug ad or imply that a doctor recommends or developed the product. In the US, a claim to treat a skin condition, eczema included, makes the product a drug.

Korea's rules bar ads that say or imply a doctor, pharmacist or other medical expert recommended, developed or uses the product (Medigate News). MFDS added examples such as "for hospital use" and doctor recommendations to its banned-expression guide in January 2025 (News Seoul). Enforcement is active: a July 2026 sweep flagged 178 online cosmetic ads, and 142 of them (80%) could be mistaken for drug ads (Cosinkorea).

Some skin-condition benefits are allowed in Korea, but only as reviewed functional cosmetics. The 2017 expansion added hair-loss relief and acne-prone skin. The former atopic category was later rewritten as products that help relieve itching by restoring a damaged skin barrier (Energy Economy News).

In the US, intended use decides (FDA). An itch or eczema claim makes the product a drug. One OTC route is the skin protectant monograph, which sets colloidal oatmeal at a 0.007% minimum and fixes the label wording (21 CFR Part 347). Acne and dandruff claims follow their own OTC rules, covered in our salicylic acid guide and zinc pyrithione guide.

Undefined words are not a shortcut. The FDA says there is no federal standard for "hypoallergenic" (FDA). A dermatologist endorsement is legal in US advertising. The FTC expects the expert to be qualified and to have examined or tested the product, with any material connection disclosed (FTC).

Is the Derma Segment Right for Your Brand?

It fits when you can name a proof asset, budget for claim-matched testing and keep every claim cosmetic. It does not fit when the clinical look is all you have. The competition is already here: Centellian24 posted record results in Amazon's October 2026 Prime Big Deal Days, with sales up 1,104% on the year (MediPharm Health).

• Good fit: a sensitive-skin or post-procedure comfort line with cosmetic claims, one hero ingredient and a test plan. Professional channels suit it; see our med spa channel guide.
• Good fit: a brand that can show sourcing and test documents to a buyer who asks for them.
• Poor fit: a line that needs eczema, acne or itch claims to sell in the US but has no OTC plan.
• Poor fit: a concept built on a doctor's name for Korean marketing, where that endorsement is off limits.

If it fits, sequence the work: proof asset, claim list for each market, test plan, then formula. For the US launch steps after that, use our playbook on how to sell Korean cosmetics in the US.

Frequently Asked Questions

Does "derma" on a label need approval in Korea?
No. The word is not a claim category, so no approval attaches to it. MFDS reviews functional claims, and any ad must still follow the drug-claim and medical-expert rules.

Can a Korean derma cream keep its Korean claims in the US?
Not automatically. A Korean functional claim such as itch relief from a damaged barrier is a drug claim in the US. Rewrite the US label to cosmetic claims, or build the product under the OTC monograph that covers the claim.

Do I need a pharmaceutical partner to start a derma brand?
No. The pharma-born brands won on a proof asset, not on a drug license. An indie brand can build that asset with a well-studied ingredient, documented sourcing and claim-matched testing through its ODM.

Is "dermatologist-tested" the same as "dermatologist-recommended"?
No. Tested means a test ran under a dermatologist's supervision, and you need the report behind it. Recommended is an endorsement: in the US it must meet FTC endorsement guidance, and in Korea cosmetic ads cannot claim a doctor recommends the product.

By Liz Song, K-beauty sourcing consultant.